ECSP21080966A - Derivados de 1,1-dióxido de 3-amino-4h-benzo[e][1,2,4] tiadiazina como inhibidores de mrgx2 - Google Patents

Derivados de 1,1-dióxido de 3-amino-4h-benzo[e][1,2,4] tiadiazina como inhibidores de mrgx2

Info

Publication number
ECSP21080966A
ECSP21080966A ECSENADI202180966A ECDI202180966A ECSP21080966A EC SP21080966 A ECSP21080966 A EC SP21080966A EC SENADI202180966 A ECSENADI202180966 A EC SENADI202180966A EC DI202180966 A ECDI202180966 A EC DI202180966A EC SP21080966 A ECSP21080966 A EC SP21080966A
Authority
EC
Ecuador
Prior art keywords
mrgx2
thiadiazine
benzo
inhibitors
amino
Prior art date
Application number
ECSENADI202180966A
Other languages
English (en)
Inventor
Tony Gibson
Angie Vassar
Mitsunori Kono
Steve Swann
Feng Zhou
Allison Chambers
Masaki Seto
Zenyu Shiokawa
Jason Pickens
Simone Bigi
Original Assignee
Solent Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solent Therapeutics Llc filed Critical Solent Therapeutics Llc
Publication of ECSP21080966A publication Critical patent/ECSP21080966A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/15—Six-membered rings
    • C07D285/16—Thiadiazines; Hydrogenated thiadiazines
    • C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
    • C07D285/20—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems
    • C07D285/22—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D285/24—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom
    • C07D285/26—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom substituted in position 6 or 7 by sulfamoyl or substituted sulfamoyl radicals
    • C07D285/32—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom substituted in position 6 or 7 by sulfamoyl or substituted sulfamoyl radicals with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/15—Six-membered rings
    • C07D285/16—Thiadiazines; Hydrogenated thiadiazines
    • C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
    • C07D285/20—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems
    • C07D285/22—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D285/24—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen compuestos de la Fórmula 1, tautómeros de los mismos, y sales farmacéuticamente aceptables de los compuestos o tautómeros, en donde L, R1, R2, R3, R4 y R5 son definidos en la especificación. Esta descripción también se refiere a materiales y métodos para preparar compuestos de la Fórmula 1, a las composiciones farmacéuticas que las contienen, y a su uso para tratar enfermedades, trastornos o afecciones asociadas con MRGX2.
ECSENADI202180966A 2019-04-29 2021-11-15 Derivados de 1,1-dióxido de 3-amino-4h-benzo[e][1,2,4] tiadiazina como inhibidores de mrgx2 ECSP21080966A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962840344P 2019-04-29 2019-04-29

Publications (1)

Publication Number Publication Date
ECSP21080966A true ECSP21080966A (es) 2022-01-31

Family

ID=70779887

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202180966A ECSP21080966A (es) 2019-04-29 2021-11-15 Derivados de 1,1-dióxido de 3-amino-4h-benzo[e][1,2,4] tiadiazina como inhibidores de mrgx2

Country Status (22)

Country Link
US (2) US12247015B2 (es)
EP (1) EP3962901A1 (es)
JP (1) JP7574215B2 (es)
KR (2) KR20260026093A (es)
CN (2) CN114072393B (es)
AR (1) AR119728A1 (es)
AU (1) AU2020266529B2 (es)
BR (1) BR112021021508A2 (es)
CL (1) CL2021002805A1 (es)
CO (1) CO2021014155A2 (es)
CR (1) CR20210544A (es)
DO (1) DOP2021000223A (es)
EC (1) ECSP21080966A (es)
IL (1) IL287521B2 (es)
JO (1) JOP20210275A1 (es)
MA (1) MA55804A (es)
MX (1) MX2021013135A (es)
PE (1) PE20220425A1 (es)
PH (1) PH12021552760A1 (es)
SG (1) SG11202111717XA (es)
TW (1) TWI846868B (es)
WO (1) WO2020223255A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021013135A (es) 2019-04-29 2021-11-25 Solent Therapeutics Llc Derivados de 1,1-dioxido de 3-amino-4h-benzo[e][1,2,4] tiadiazina como inhibidores de mrgx2.
TWI782504B (zh) * 2020-05-08 2022-11-01 美商美國禮來大藥廠 (三氟甲基)嘧啶-2-胺化合物
WO2022152853A1 (en) * 2021-01-15 2022-07-21 Glaxosmithkline Intellectual Property Development Limited Antagonists of mrgx2
WO2022152852A1 (en) * 2021-01-15 2022-07-21 Glaxosmithkline Intellectual Property Development Limited Antagonists of mrgx2
WO2024183806A1 (en) * 2023-03-08 2024-09-12 InventisBio Co., Ltd. Compounds, preparation methods and uses thereof
WO2025037034A1 (en) * 2023-08-17 2025-02-20 Sanofi Thienothiadiazines, their preparation and their therapeutic application
WO2025042736A1 (en) 2023-08-18 2025-02-27 Incyte Corporation Bicyclic heterocycles as mrgprx2 antagonists
TW202517273A (zh) * 2023-10-06 2025-05-01 美商伊賽恩特製藥公司 Ｍｒｇｐｒｘ２調節劑及相關治療方法
CN120230034A (zh) * 2023-12-29 2025-07-01 深圳阿尔法分子科技有限责任公司 喹诺酮类化合物及其用途
WO2025160430A1 (en) 2024-01-25 2025-07-31 Incyte Corporation Bicyclic heterocycles as mrgprx2 antagonists
WO2025222040A1 (en) 2024-04-19 2025-10-23 Escient Pharmaceuticals, Inc. Mrgprx2 modulators for use in treating mrgprx2 dependent conditions in subjects with low ige
JP2026009006A (ja) * 2024-07-01 2026-01-19 日本たばこ産業株式会社 ピリダジノン化合物及びその医薬用途
WO2026033047A1 (en) * 2024-08-08 2026-02-12 Glaxosmithkline Intellectual Property Development Limited Benzothiadiazine derivatives as mrgx2 antagonists

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2757999A1 (de) * 1977-12-24 1979-06-28 Bayer Ag Substituierte aminoalkylenamino- 1.2.4-benzothiadiazine, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
EP0105732A3 (en) 1982-10-01 1985-09-04 Beecham Group Plc Histamine h2 receptor antagonists of the benzisothiazole amino and benzthiadiazine amino series
EP0386931A1 (en) 1989-03-04 1990-09-12 Konica Corporation A novel cyan coupler
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
US6242443B1 (en) 1996-06-21 2001-06-05 Novo Nordisk Ais 1,2,4-benzothiadiazine derivatives, their preparation and use
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
AU1555999A (en) 1997-12-19 1999-07-12 Novo Nordisk A/S 1,2,4-benzothiadiazine derivatives, their preparation and use
CN1293665A (zh) 1998-02-18 2001-05-02 神经研究公司 新化合物及其用作阳性ampa受体调节剂
JP2004533840A (ja) 2001-07-06 2004-11-11 ジェネンテック・インコーポレーテッド ファージディスプレイによるｐｄｚドメインリガンド
EP1340979A3 (en) 2002-02-27 2004-02-04 Pfizer Limited Neuropeptide receptor and uses thereof
CA2484261A1 (en) 2002-04-16 2003-10-23 Teijin Limited Piperidine derivatives having ccr3 antagonism
EP1505067A4 (en) 2002-04-25 2006-06-21 Teijin Ltd 4,4-DISUBSTITUTED PIPERIDINE DERIVATIVES WITH CCR3 ANTAGONISM
AU2003238287A1 (en) 2002-06-21 2004-01-06 California Institute Of Technology Identification of a receptor controlling migration and metastasis of skin cancer cells
WO2005019191A2 (en) 2003-08-25 2005-03-03 Abbott Laboratories 1, 1-dioxido-4h-1,2,4-benzothiadiazine derivate und verwandte verbindungen als inhibitoren der hcv polymerase zur behandlung von hepatitis c
JPWO2005028667A1 (ja) 2003-09-19 2006-11-30 独立行政法人理化学研究所 ヒト肥満細胞で発現するｇ蛋白質共役型受容体を標的とした薬剤およびそのスクリーニング方法
JP4533391B2 (ja) 2004-01-16 2010-09-01 エフ．ホフマン−ラ ロシュ アーゲー 中枢神経系疾患の処置のための５−ヒドロキシトリプタミンレセプター（５−ｈｔ）のモジュレーターとしての、１−ベンジル−５−ピペラジン−１−イル−３，４−ジヒドロ−１ｈ−キナゾリン−２−オン誘導体、ならびにそれぞれの１ｈ−ベンゾ（１，２，６）チアジアジン−２，２−ジオキシドおよび１，４−ジヒドロベンゾ（ｄ）（１，３）オキサジン−２−オン誘導体
US20060223131A1 (en) 2004-09-15 2006-10-05 Barry Schweitzer Protein arrays and methods of use thereof
EP1820360B1 (en) 2004-12-08 2013-02-27 Electronics and Telecommunications Research Institute Method of controlling base stations to suppress inter-cell interference
US20060217370A1 (en) * 2005-02-18 2006-09-28 Ethan Burstein Compounds useful for the treatment and prevention of pain and screening methods therefor
CA2604333A1 (en) 2005-04-15 2006-10-19 Cenix Bioscience Gmbh Human marker genes and agents for cardiovascular disorders and artherosclerosis
US20100068208A1 (en) 2005-04-28 2010-03-18 Kazuhiro Ogi Degranulation inhibitor
WO2007032793A1 (en) 2005-05-27 2007-03-22 Sentigen Bioscience, Inc. Multiplex array useful for assaying protein-protein interaction
AU2006308991A1 (en) 2005-10-31 2007-05-10 University Of Rochester Chemical preconditioning as a preventative or treatment for excitotoxic synaptic damage
JP2009060787A (ja) 2005-11-15 2009-03-26 Gunma Univ Ｒｅｃ１６８を介する肥満細胞の脱顆粒反応を抑制する物質のスクリーニング方法及び同定方法、並びにＲｅｃ１６８アンタゴニストを含有してなる肥満細胞が関与する炎症性疾患の治療剤
JP2010505897A (ja) 2006-10-11 2010-02-25 マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ インフルエンザターゲット
WO2008052072A2 (en) * 2006-10-24 2008-05-02 Acadia Pharmaceuticals Inc. Compounds for the treatment of pain and screening methods therefor
EP2091556B1 (en) 2006-11-15 2018-07-25 Omeros Corporation Non-human animal comprising a mutation in the sreb2/gpr85 gene as animal model of metabolic disease
UA100120C2 (en) 2007-04-03 2012-11-26 Анадис Фармасьютикалз, Инк. 5,6-dihydro-1h-pyridin-2-one compounds
EP2067861A1 (en) 2007-12-05 2009-06-10 Koninklijke Nederlandse Akademie van Wetenschappen Animals of the rattus genus wherein msh6 expression is functionally decreased and methods for the generation of specific mutants therefrom
JP2012167017A (ja) 2009-06-15 2012-09-06 National Cerebral & Cardiovascular Center ペプチドおよびその用途
JP5996429B2 (ja) 2009-09-03 2016-09-21 ジェネンテック， インコーポレイテッド 関節リウマチの治療、診断及びモニターするための方法
IT1402905B1 (it) 2010-11-29 2013-09-27 Univ Degli Studi Modena E Reggio Emilia Derivati di 1,2,4-benzotiadiazin 1,1-diossido, loro preparazione e loro impiego come modulatori allosterici del recettore ampa.
JP5932279B2 (ja) 2011-10-07 2016-06-08 ポーラ化成工業株式会社 スクリーニング方法
WO2013130411A1 (en) 2012-02-27 2013-09-06 Essentialis, Inc. Salts of potassium atp channel openers and uses thereof
WO2014055955A1 (en) 2012-10-05 2014-04-10 Rigel Pharmaceuticals, Inc. Gdf-8 inhibitors
WO2014202515A1 (en) 2013-06-18 2014-12-24 Bayer Pharma Aktiengesellschaft Mrg receptor modulators
US10981951B2 (en) 2014-01-31 2021-04-20 Mayo Foundation For Medical Education And Research Therapeutics for the treatment of glaucoma
CN106536507B (zh) 2014-04-08 2020-04-07 里格尔药品股份有限公司 作为TGF-β抑制剂的2,3-二取代的吡啶化合物及其使用方法
WO2016118632A1 (en) 2015-01-20 2016-07-28 The General Hospital Corporation Prevention and treatment of itch with an mrgpr antagonist
WO2017095759A1 (en) 2015-12-04 2017-06-08 Merck Sharp & Dohme Corp. C5-c6-carbocyclic fused iminothiadiazine dioxides as bace inhibitors, compositions, and their use
WO2017098421A1 (en) 2015-12-08 2017-06-15 Glaxosmithkline Intellectual Property Development Limited Benzothiadiazine compounds
EP3606921B1 (en) 2017-04-06 2022-06-01 Inventiva New compounds inhibitors of the yap/taz-tead interaction and their use in the treatment of malignant mesothelioma.
US11370822B2 (en) 2017-05-26 2022-06-28 The Governors Of The University Of Alberta Self-assembling peptide for activating human mast cells
KR102767739B1 (ko) 2018-06-27 2025-02-12 브리스톨-마이어스 스큅 컴퍼니 T 세포 활성화제로서 유용한 치환된 나프티리디논 화합물
EP3597653A1 (en) 2018-07-19 2020-01-22 Irbm S.P.A. Cyclic inhibitors of hepatitis b virus
MX2021013135A (es) 2019-04-29 2021-11-25 Solent Therapeutics Llc Derivados de 1,1-dioxido de 3-amino-4h-benzo[e][1,2,4] tiadiazina como inhibidores de mrgx2.

Also Published As

Publication number Publication date
CN114072393A (zh) 2022-02-18
CN114072393B (zh) 2025-05-27
MX2021013135A (es) 2021-11-25
BR112021021508A2 (pt) 2022-03-22
IL287521B2 (en) 2026-01-01
CL2021002805A1 (es) 2022-07-22
SG11202111717XA (en) 2021-11-29
JP2022535672A (ja) 2022-08-10
EP3962901A1 (en) 2022-03-09
KR20260026093A (ko) 2026-02-25
CN120535477A (zh) 2025-08-26
AR119728A1 (es) 2022-01-05
US20250289792A1 (en) 2025-09-18
CA3137584A1 (en) 2020-11-05
DOP2021000223A (es) 2022-01-16
TW202106669A (zh) 2021-02-16
CR20210544A (es) 2022-03-30
US12247015B2 (en) 2025-03-11
JOP20210275A1 (ar) 2023-01-30
IL287521B1 (en) 2025-09-01
KR20220012244A (ko) 2022-02-03
IL287521A (en) 2021-12-01
PH12021552760A1 (en) 2022-08-15
KR102922478B1 (ko) 2026-02-04
PE20220425A1 (es) 2022-03-29
AU2020266529B2 (en) 2026-01-29
AU2020266529A1 (en) 2021-12-16
WO2020223255A1 (en) 2020-11-05
JP7574215B2 (ja) 2024-10-28
CO2021014155A2 (es) 2021-10-29
MA55804A (fr) 2022-04-06
US20220119361A1 (en) 2022-04-21
TWI846868B (zh) 2024-07-01

Similar Documents

Publication Publication Date Title
ECSP21080966A (es) Derivados de 1,1-dióxido de 3-amino-4h-benzo[e][1,2,4] tiadiazina como inhibidores de mrgx2
DOP2022000057A (es) Derivados de piridazin-3(2h)-ona fusionados con azol
CO2022000480A2 (es) Compuestos 2,3-dihidroquinazolin como inhibidores nav1.8
BR112022016382A2 (pt) Triptaminas específicas para o uso no tratamento de doenças do humor
ECSP21034668A (es) Derivados de 2,3-dihidro-1h-pirrolo[3,4-c]piridin-1-ona como inhibidores de hpk1 para el tratamiento de cáncer
MX381041B (es) Compuesto cíclico tipo cumarina como inhibidor de mek y su uso.
PY1923494A (es) Derivados de n-(3-(7h-pirrolo[2,3-d]pirimidin-4-il)fenil)benzamida
PE20050089A1 (es) Derivados de azo [1,2-c] quinazolina condensados
UY30327A1 (es) Nuevos compuestos ii
UY32462A (es) Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644
UY35376A (es) Derivados de triazolona de piridinilo y piridinilo fusionado
UY29420A1 (es) Derivados de 2-piridona,composiciones que los contienen, procesos de preparación y aplicación
MX2020007443A (es) Derivados de 2,4,6,7-tetrahidro-pirazolo[4,3-d]pirimidin-5-ona y compuestos relacionados como moduladores del receptor c5a para el tratamiento de vasculitis y enfermedades inflamatorias.
UY28356A1 (es) Derivados de benzimidazol, composiciones que los contienen, preparaciones de los mismos y sus usos
ECSP22091230A (es) Derivados de n-(piperidin-4-il)benzamida de acción luminal
CL2020000439A1 (es) Sales de un compuesto y sus formas cristalinas.
CL2022002692A1 (es) Derivados de n-(heterociclil y heterociclilalquil)-3-bencilpiridin-2-amina como agonistas de sstr4
UY38278A (es) Agentes inhibidores de ask1
CL2024000317A1 (es) Derivados de ciclopentatiofencarboxamida como antagonistas del receptor del factor de activación de plaquetas
CO2021003218A2 (es) Agentes inhibidores de ask1
DOP2017000138A (es) Derivados de fumagilol
ECSP18056196A (es) Derivados de indano
UY28711A1 (es) Derivados heterociclicos
UY40681A (es) COMPUESTOS DE 1-H-PIRROLO[2,3-c]PIRIDINA
AR049638A1 (es) Derivados de benzileter, su elaboracion, su uso para preparar agentes farmaceuticos y composicion farmaceutica